Department of Clinical and Experimental Cardiology, Heart Center, University of Amsterdam, Amsterdam UMC, 1105 AZ Amsterdam, The Netherlands.
Int J Mol Sci. 2021 Jun 15;22(12):6422. doi: 10.3390/ijms22126422.
In the two decades since the discovery of TNNI3K it has been implicated in multiple cardiac phenotypes and physiological processes. TNNI3K is an understudied kinase, which is mainly expressed in the heart. Human genetic variants in are associated with supraventricular arrhythmias, conduction disease, and cardiomyopathy. Furthermore, studies in mice implicate the gene in cardiac hypertrophy, cardiac regeneration, and recovery after ischemia/reperfusion injury. Several new papers on TNNI3K have been published since the last overview, broadening the clinical perspective of variants and our understanding of the underlying molecular biology. We here provide an overview of the role of TNNI3K in cardiomyopathy and arrhythmia covering both a clinical perspective and basic science advancements. In addition, we review the potential of TNNI3K as a target for clinical treatments in different cardiac diseases.
自 TNNI3K 被发现以来的二十年中,它已涉及多种心脏表型和生理过程。TNNI3K 是一种研究不足的激酶,主要在心脏中表达。 中的人类遗传变异与室上性心律失常、传导疾病和心肌病有关。此外,在小鼠中的研究表明该基因与心脏肥大、心脏再生和缺血/再灌注损伤后的恢复有关。自上次综述以来,已有几篇关于 TNNI3K 的新论文发表,拓宽了 变异的临床视角和我们对潜在分子生物学的理解。在这里,我们概述了 TNNI3K 在心肌病和心律失常中的作用,涵盖了临床和基础科学的进展。此外,我们还回顾了 TNNI3K 作为不同心脏疾病临床治疗靶点的潜力。